Inmune Bio Stock Investor Sentiment

INMB Stock  USD 7.95  0.09  1.12%   
About 63% of INmune Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding INmune Bio suggests that many traders are alarmed. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
  
six days ago at www.macroaxis.com         
Acquisition by Lowdell Mark William of 140000 shares of INmune Bio at 5.05 subject to Rule 16b-3
Macroaxis News
over a week ago at www.macroaxis.com         
Acquisition by Baracchini Edgardo Jr of 35000 shares of INmune Bio subject to Rule 16b-3
Macroaxis News
over a week ago at news.google.com         
INmune Bio Reports Promising Phase III Trial Results - TipRanks
Google News at Macroaxis
over a week ago at news.google.com         
Why INmune Bio, Inc. is Skyrocketing So Far in 2025 - MSN
Google News at Macroaxis
over a week ago at finance.yahoo.com         
Why INmune Bio, Inc. is Skyrocketing So Far in 2025
Yahoo News
over two weeks ago at simplywall.st         
Is INmune Bio A Risky Investment?
Simply Wall St News at Macroaxis
over three weeks ago at finance.yahoo.com         
INmune Bio, Inc. most popular amongst individual investors who own 36 percent of the shares, institu...
Yahoo News
over three weeks ago at thelincolnianonline.com         
INmune Bio, Inc. Short Interest Update
news
over a month ago at thelincolnianonline.com         
INmune Bio Price Target Raised to 23.00 at Scotiabank
news
over a month ago at gurufocus.com         
INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer
Yahoo News
over a month ago at globenewswire.com         
INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer
Macroaxis News: globenewswire.com
over a month ago at thelincolnianonline.com         
INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc...
news
over a month ago at gurufocus.com         
INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of ...
Gurufocus Stories at Macroaxis
over a month ago at globenewswire.com         
INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of CORDStrom ...
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. That information is available publicly through INmune media outlets and privately through word of mouth or via INmune internal channels. However, regardless of the origin, that massive amount of INmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.

INmune Bio Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for INmune Stock analysis

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Stocks Directory
Find actively traded stocks across global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Fundamental Analysis
View fundamental data based on most recent published financial statements
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios